title: Tyrosine kinase inhibitors in advanced NSCLC: A case report.
abstract: Erlotinib is a molecule that selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase activity. The authors present a case that exemplifies the use of erlotinib as second line therapy for non-small cell lung cancer (NSCLC). This case is about a 76 years old woman, non-smoker, with advanced lung adenocarcinoma (stage IIIB) previously treated with two cycles of standard chemotherapy, which were interrupted by serious adverse reactions. Rev Port Pneumol 2008; XIV (Supl 3): S23-S28.
authors.affiliation: Interna do Internato Complementar de Pneumologia, Serviço de Pneumologia - Hospital de Santarém, EPE. Electronic address: amf.alves@gmail.com.
authors.forename: Ana Ferreira
authors.initials: AF
authors.lastname: Alves
authors.affiliation: Chefe de Serviço de Pneumologia, Serviço de Pneumologia - Hospital de Santarém, EPE.
authors.forename: Marco
authors.initials: M
authors.lastname: Liebermann
keywords: Cancro do pulmão; Lung cancer; adenocarcinoma; erlotinib